Literature DB >> 23749525

The new kid on the block: RET in lung cancer.

Justin F Gainor1, Alice T Shaw.   

Abstract

RET has recently been identified as a potential new oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23749525     DOI： 10.1158/2159-8290.CD-13-0174

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  7 in total

Review 1.  Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

Authors:  Christine Khoo; Toni-Maree Rogers; Andrew Fellowes; Anthony Bell; Stephen Fox
Journal:  Transl Lung Cancer Res       Date:  2015-04

2.  New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.

Authors:  Juliane M Jürgensmeier; Joseph P Eder; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2014-09-01       Impact factor: 12.531

Review 3.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

Review 4.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

5.  Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.

Authors:  Zhonghua Tao; Jianxia Liu; Ting Li; Hong Xu; Kai Chen; Jian Zhang; Hao Zhou; Jie Sun; Jinming Han; Zhaoji Guo; Hua Yang; Wen-Ming Cao; Xichun Hu
Journal:  Front Oncol       Date:  2021-09-28       Impact factor: 6.244

6.  RET rearrangements are actionable alterations in breast cancer.

Authors:  Bhavna S Paratala; Jon H Chung; Casey B Williams; Bahar Yilmazel; Whitney Petrosky; Kirstin Williams; Alexa B Schrock; Laurie M Gay; Ellen Lee; Sonia C Dolfi; Kien Pham; Stephanie Lin; Ming Yao; Atul Kulkarni; Frances DiClemente; Chen Liu; Lorna Rodriguez-Rodriguez; Shridar Ganesan; Jeffrey S Ross; Siraj M Ali; Brian Leyland-Jones; Kim M Hirshfield
Journal:  Nat Commun       Date:  2018-11-16       Impact factor: 14.919

7.  Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.

Authors:  Aparna Hegde; Alexander Y Andreev-Drakhlin; Jason Roszik; Le Huang; Shuang Liu; Kenneth Hess; Maria Cabanillas; Mimi I Hu; Naifa L Busaidy; Steven I Sherman; Ramona Dadu; Elizabeth G Grubbs; Siraj M Ali; Jessica Lee; Yasir Y Elamin; George R Simon; George R Blumenschein; Vassiliki A Papadimitrakopoulou; David Hong; Funda Meric-Bernstam; John Heymach; Vivek Subbiah
Journal:  ESMO Open       Date:  2020-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.